Severe Dyslipidaemia after the Addition of Raltegravir to a Lopinavir/Ritonavir-Containing Regimen

We describe a 55-year-old HIV-1-infected male who developed severe dyslipidaemia (total cholesterol 600 mg/dl, triglycerides >5,000 mg/dl, high density lipoprotein

Saved in:
Bibliographic Details
Published in:Antiviral therapy 2012-01, Vol.17 (7), p.1385-1388
Main Authors: Huesgen, Emily, Burgos, Rodrigo, Goldstein, Debra A, Max, Blake, Jarrett, Olamide D
Format: Article
Language:English
Subjects:
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Biological and medical sciences
Cholesterol
Cholesterol, HDL - blood
Drug interaction
Drug Interactions
Drug Therapy, Combination
Dyslipidemias - chemically induced
Dyslipidemias - pathology
HIV Infections - complications
HIV Infections - drug therapy
HIV Infections - virology
HIV Protease Inhibitors - adverse effects
HIV Protease Inhibitors - therapeutic use
HIV-1 - pathogenicity
Human immunodeficiency virus
Humans
Lipids
Lipoproteins (high density)
Lopinavir
Lopinavir - adverse effects
Lopinavir - therapeutic use
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Pyrrolidinones - adverse effects
Pyrrolidinones - therapeutic use
Raltegravir Potassium
Ritonavir
Ritonavir - adverse effects
Ritonavir - therapeutic use
Treatment Outcome
Triglycerides
Triglycerides - blood
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We describe a 55-year-old HIV-1-infected male who developed severe dyslipidaemia (total cholesterol 600 mg/dl, triglycerides >5,000 mg/dl, high density lipoprotein
ISSN:1359-6535
2040-2058
DOI:10.3851/IMP2182